Gregory Gallousis, MD
Ophthalmology · Stamford, CTNPI 1548202534
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 205 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 50.0% of the total. 2025 is the largest year on record at $2,534, 5.7 times the $443 reported in 2019. Among ophthalmology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 205 payments — averaging $48.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Alcon$1K
- Glaukos Corporation$1K
- Sight Sciences, Inc.$348
- Tarsus Pharmaceuticals, Inc.$324
- Aerie Pharmaceuticals, Inc.$263
- plus $2K from 17 others
What the payments were for
- Food & beverage$9,826100%
- Gifts$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 96 | $4,937 |
| Alcon | 26 | $1,309 |
| Glaukos Corporation | 14 | $1,158 |
| Sight Sciences, Inc. | 4 | $348 |
| Tarsus Pharmaceuticals, Inc. | 8 | $324 |
| Aerie Pharmaceuticals, Inc. | 3 | $263 |
| Ivantis, Inc | 2 | $206 |
| Biotissue Holdings Inc. | 4 | $179 |
| Sun Pharmaceutical Industries Inc. | 9 | $176 |
| Kala Pharmaceuticals, Inc. | 7 | $163 |
| Novartis | 3 | $152 |
| Rayner Intraocular Lenses Limited | 6 | $151 |
| Bausch & Lomb Americas Inc. | 8 | $145 |
| Ocular Therapeutix, Inc. | 4 | $73 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $61 |
| Oyster Point Pharma, Inc. | 2 | $55 |
| Amgen | 2 | $41 |
| Nova Eye, Inc. | 1 | $29 |
| Iridex Corporation | 1 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Thea Pharma Inc. | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $17 |
| Visionix USA, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$1,632
- DURYSTA$1,240
- iDoseTR$442
- Rocklatan$385
- iStent Trabecular Micro-Bypass System Model iS3$257
- Rhopressa$238
- Hydrus Microstent$184
- iDose$178
- Prokera$150
- PanOptix$148
- AcrySof IQ VIVITY$143
- Hydrus$125
- XDEMVY$124
- OMNI$123
- OMNI(R) SURGICAL SYSTEM (US)$121
- AcrySof IQ VIVITY IOL$120
- TRAVATAN Z$118
- Clareon PanOptix Pro$117
- Clareon$117
How this compares
$9,871 in reported general payments places this provider in the 90th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 84 | $38,020 |
| ProlensaBromfenac Sodium | 55 | $19,343 |
| XiidraLifitegrast | 16 | $15,630 |
| RocklatanNetarsudil Mesylat/Latanoprost | 29 | $14,950 |
| RhopressaNetarsudil Mesylate | 29 | $11,683 |
| Alphagan PBrimonidine Tartrate | 18 | $7,883 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 80 | $7,084 |
| RestasisCyclosporine | 11 | $7,023 |
| CombiganBrimonidine Tartrate/Timolol | 25 | $6,725 |
| Prednisolone Acetate | 198 | $6,050 |
| Brimonidine Tartrate | 76 | $3,708 |
| Timolol Maleate | 174 | $3,396 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $2,874 |
| Travoprost | 40 | $2,844 |
| Brinzolamide | 28 | $2,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Restasis, Combigan | $4,937 | $59,650138 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $263 | $26,63358 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $17 | $19,34355 claims |
| Bausch & Lomb Americas Inc.Xiidra | $145 | $15,63016 claims |
| AlconSimbrinza | $1,309 | $2,87414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 279 ophthalmology providers in Connecticut.
Other ophthalmology in Stamford
- Lauren SchneiderStamford$4K
- Robert FucignaStamford$3K
- John HuangHartford$267K
- Amir CohenNew Haven$266K
- James MurphyHamden$176K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
- Anish ShahNorwich$38K
- Michael KovalFarmington$35K
- Scott SpectorNorwalk$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.